Monthly Archives: October 2015

Kayexalate (sodium polystyrene sulfonate): Drug Safety Communication – FDA Requires Drug Interaction Studies

Audience: Internal Medicine, Nephrology, Cardiology ISSUE: FDA is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate’s potential to bind to other medications administered by mouth – drug interactions that could...

Read More »

Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication – Risk of Serious Liver Injury

Audience: Patient, Infectious Disease, Pharmacy ISSUE: FDA is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, FDA is requiring the...

Read More »

Drug Products Intended to be Sterile by Chen Shwezin Inc., dba Park Compounding Pharmacy: FDA Statement – Lack of Sterility Assurance

Audience: Pharmacy, Compounding, Nursing, Risk Manager [Posted 10/03/2015] ISSUE: During FDA’s recent inspection of Park Compounding Pharmacy’s facility, FDA investigators observed insanitary conditions, including poor sterile production...

Read More »